Literature DB >> 20526784

Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies.

Douglas E Peterson1, Wolfgang Doerr, Allan Hovan, Andres Pinto, Debbie Saunders, Linda S Elting, Fred K L Spijkervet, Michael T Brennan.   

Abstract

PURPOSE: The purpose of this study is to review the evidence base from 1990 to 2008 to (1) clarify the impact of cancer therapies on prevalence of osteoradionecrosis (ORN) in head and neck cancer patients, and to (2) evaluate management strategies and their consequences on quality of life and cost of care.
METHODS: Articles were selected for the time period beginning after 1989, excluding the 1990 NCI monograph articles from the 1989 NIH-sponsored Oral Complications in Cancer Therapy Symposium that was published in 1990. The search included both Medline/PubMed and Embase and was limited to humans. The search was limited to publications in the English language. No abstracts were utilized in the current review. Each article was evaluated by two reviewers. A weighted prevalence was calculated for the prevalence of ORN while incorporating predetermined quality measures. The level of evidence, recommendation grade, and guideline (if possible) were provided for published preventive and management strategies for ORN.
RESULTS: A total of 43 articles between 1990 and 2008 were reviewed. The weighted prevalence for ORN included conventional radiotherapy (RT) = 7.4%, intensity modulated RT (IMRT) = 5.1%, chemoradiotherapy (CRT) = 6.8%, and brachytherapy = 5.3%. Hyperbaric oxygen may contribute a role in management of ORN. However, no clear guideline recommendations could be established for the prevention or treatment of ORN based on the literature reviewed.
CONCLUSIONS: New cancer treatment modalities such as IMRT and concomitant CRT have had minimal effect on prevalence of ORN. No studies to date have systematically addressed impact of ORN on either quality of life or cost of care.

Entities:  

Mesh:

Year:  2010        PMID: 20526784     DOI: 10.1007/s00520-010-0898-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  50 in total

1.  Combining studies using effect sizes and quality scores: application to bone loss in postmenopausal women.

Authors:  A Bérard; G Bravo
Journal:  J Clin Epidemiol       Date:  1998-10       Impact factor: 6.437

Review 2.  Osteoradionecrosis of the jaws as a risk factor in radiotherapy: a report of an eight-year retrospective review.

Authors:  J A Toljanic; M Ali; D J Haraf; E E Vokes; W J Moran; L Graham
Journal:  Oncol Rep       Date:  1998 Mar-Apr       Impact factor: 3.906

3.  Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.

Authors:  R De Crevoisier; C Domenge; P Wibault; S Koscielny; A Lusinchi; F Janot; S Bobin; B Luboinski; F Eschwege; J Bourhis
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

4.  Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997.

Authors:  G G Grabenbauer; C Rödel; T Brunner; S Schulze-Mosgau; V Strnad; R G Müller; H Iro; R Sauer
Journal:  Strahlenther Onkol       Date:  2001-07       Impact factor: 3.621

5.  Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group.

Authors:  Djillali Annane; Joël Depondt; Philippe Aubert; Maryvonne Villart; Pierre Géhanno; Philippe Gajdos; Sylvie Chevret
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

6.  High-dose rate interstitial brachytherapy for stage I-II tongue cancer.

Authors:  M Umeda; H Komatsubara; N Nishimatsu; S Yokoo; Y Shibuya; T Komori
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2000-11

7.  Review of severe osteoradionecrosis treated by surgery alone or surgery with postoperative hyperbaric oxygenation.

Authors:  A Maier; A Gaggl; H Klemen; G Santler; U Anegg; B Fell; H Kärcher; F M Smolle-Jüttner; G B Friehs
Journal:  Br J Oral Maxillofac Surg       Date:  2000-06       Impact factor: 1.651

8.  Factors affecting mandibular complications in low dose rate brachytherapy for oral tongue carcinoma with special reference to spacer.

Authors:  M Miura; M Takeda; T Sasaki; T Inoue; T Nakayama; H Fukuda; A Hoshi; M Hoshina; H Shibuya
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-01       Impact factor: 7.038

9.  Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.

Authors:  P D Maguire; M B Meyerson; C R Neal; M S Hamann; A L Bost; J W Anagnost; P C Ungaro; H D Pollock; J E McMurray; E P Wilson; C A Kotwall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

10.  An analysis of mandibular bone complications in radiotherapy for T1 and T2 carcinoma of the oral tongue.

Authors:  M Fujita; Y Hirokawa; K Kashiwado; Y Akagi; K Kashimoto; H Kiriu; K Ohtani; T Wada
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-01-15       Impact factor: 7.038

View more
  25 in total

1.  [Analysis of the risk factors of radiation-induced caries in patients with head and neck cancer].

Authors:  Li-Ling Wu; Qing-Ping Gao; Qiong-Yao Fu; Kun Geng
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2019-02-01

2.  Introduction of a head and neck cancer dental screening pro forma.

Authors:  J Ban; S Ali; A Barber; L McNally
Journal:  Br Dent J       Date:  2018-09-21       Impact factor: 1.626

Review 3.  Surgery Versus Radiotherapy for Early Oropharyngeal Tumors: a Never-Ending Debate.

Authors:  Yan Monnier; Christian Simon
Journal:  Curr Treat Options Oncol       Date:  2015-09

4.  Periodontal care in patients undergoing radiotherapy for head and neck cancer.

Authors:  Audrey Cristina Bueno; Raquel Conceição Ferreira; Flávia Isabela Barbosa; Bruno Correia Jham; Cláudia Silami Magalhães; Allyson Nogueira Moreira
Journal:  Support Care Cancer       Date:  2012-10-02       Impact factor: 3.603

5.  Dental disease before radiotherapy in patients with head and neck cancer: Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients.

Authors:  Michael T Brennan; Nathaniel S Treister; Thomas P Sollecito; Brian L Schmidt; Lauren L Patton; Kusha Mohammadi; Leslie Long Simpson; Helen Voelker; James S Hodges; Rajesh V Lalla
Journal:  J Am Dent Assoc       Date:  2017-12       Impact factor: 3.634

6.  A retrospective study of outcomes in subjects of head and neck cancer treated with hyperbaric oxygen therapy for radiation induced osteoradionecrosis of mandible at a tertiary care centre: an Indian experience.

Authors:  Puneet Gupta; Tarun Sahni; G K Jadhav; Sapna Manocha; Shweta Aggarwal; Sapna Verma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-03-31

7.  The association between dental therapy timelines and osteoradionecrosis: a nationwide population-based cohort study.

Authors:  Yi-Fang Huang; Shih-Ping Liu; Chih-Hsin Muo; Chun-Hao Tsai; Chung-Ta Chang
Journal:  Clin Oral Investig       Date:  2019-05-20       Impact factor: 3.573

Review 8.  Treatment of late sequelae after radiotherapy for head and neck cancer.

Authors:  Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Treat Rev       Date:  2017-07-18       Impact factor: 12.111

9.  Interventions for preventing osteoradionecrosis of the jaws in adults receiving head and neck radiotherapy.

Authors:  Mohamed El-Rabbany; Michael Duchnay; Hamid Reza Raziee; Maria Zych; Howard Tenenbaum; Prakeshkumar S Shah; Amir Azarpazhooh
Journal:  Cochrane Database Syst Rev       Date:  2019-11-20

10.  When the tumour is not the culprit: avascular necrosis of the hip in a patient with castration-resistant prostate cancer.

Authors:  E Chan; G Chan; L Ehrlich; P Hull; H Kreder; W Chu; E Chow; U Emmenegger
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.